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Background: Oxytocin may cause adverse cardiovascular effects, including tachycardia and hypotension, whereas 
the optimal dose of oxytocin at elective cesarean section is unclear. To determine the lowest effective dose of 
oxytocin, we studied the hemodynamic effects of three doses during spinal anesthesia for elective single cesarean 
delivery.
Methods: Sixty women received oxytocin by continuous (0.5 IU/min) or bolus-continuous (2 or 5 IU prior to 0.25 
IU/min continuous intravenous injection) intravenous injection after clamping of the umbilical cord. We compared 
changes in heart rate (HR), mean arterial pressure (MAP) and estimated blood loss (EBL). Uterine tone (UT) was 
assessed by palpation on a linear analog scale (LAS) at 5, 10, 15, 20 and 25 minutes after the oxytocin injection. In 
addition, oxytocin-related side-effects such as nausea and vomiting were recorded.
Results: Marked hemodynamic changes such as HR and MAP occurred in the bolus-continuous groups but not in 
the continuous groups. Although we were not able to observe a variation of EBL in each group, the UT significantly 
increased in the bolus-continuous groups when compared with that the continuous groups. In addition, the 
hemodynamic changes such as HR and MAP were lower in the two IU bolus-continuous group than those in the five 
IU group.
Conclusions: Although bolus-continuous injection of oxytocin resulted in more hemodynamic changes than 
continuous injection, bolus-continuous injection had a greater effect on uterine contraction. Furthermore, two IU 
bolus-continuous injection showed lower hemodynamic changes than in the five IU bolus-continuous injection. 
(Korean J Anesthesiol 2011; 61: 482-487)
Key Words:  Bolus-continuous intravenous injection, Continuous intravenous injection, Elective cesarean section, 
Oxytocin, Spinal anesthesia.
Hemodynamic effects of continuous intravenous injection 
and bolus plus continuous intravenous injection of oxytocin 
in cesarean section
Tae-Sung Kim, Jun-Seok Bae, Jung-Man Park, and Sin-Kyu Kang
Department of Anesthesiology and Pain Medicine, St. Mary' s Hospital, Busan, Korea 
Received: March 22, 2011.  Revised: 1st, May 16, 2011; 2nd, June 3, 2011.  Accepted: June 7, 2011.
Corresponding author: Jun-Seok Bae, M.D., Department of Anesthesiology and Pain Medicine, St. Mary' s Hospital, 538-41, Yongho-dong, 
Nam-gu, Busan 608-838, Korea. Tel: 82-51-933-7363, Fax: 82-51-932-8600, E-mail: soaf29@naver.com
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC
Copyright ⓒ the Korean Society of Anesthesiologists, 2011 www.ekja.org483 www.ekja.org
Korean J Anesthesiol Kim, et al.
Introduction
The hemodynamic changes in parturient women after 
cesarean delivery may be caused by the elimination of the 
aorta-caval compression, autotransfusion of uterine con-
traction, hemorrhage, and vasoconstriction and excitation, but 
some studies have reported that uterotonic drug is the main 
factor [1,2]. Uterotonic drug, which is most frequently used for 
cesarean section, is oxytocin, which induces uterine contraction 
during cesarean section and peripheral vasodilation along with 
a decrease in arterial pressure after delivery and thus, reduces 
hemorrhage [3,4]. However, intravenous injection of oxytocin 
during cesarean section may cause cardiovascular side effects 
such as tachycardia or hypotension [1,2] and is reported to 
cause even cardiovascular collapse and death in the most 
severe cases [5,6]. Moreover, various other side effects have 
been reported including fluid pooling or pulmonary edema by 
the antidiuretic effect of oxytocin [7-9].
Hence, determining the oxytocin concentration for cesarean 
section is important. However, since the activity of oxytocin 
varies from individual to individual [10] and an appropriate 
dose has not been established, 5-20 IU is intravenously injected 
based on experience [11,12]. There is a recent assertion that 
bolus intravenous injection or bolus-continuous parallel 
intravenous injection of oxytocin is more effective than 
continuous intravenous injection in cesarean section [13,14]. 
There is also a report that a great quantity of bolus intravenous 
injection requires caution because it causes hemodynamic 
changes related to hypotension [1,2]. Therefore, research is 
necessary on the method of oxytocin injection and the effective 
minimum concentration for cesarean section to induce uterine 
contraction without side effects.
In this study, we did continuous intravenous injection 
or bolus-continuous intravenous injection of oxytocin after 
clamping of the umbilical cord during planned cesarean 
sections under spinal anesthesia, and investigated the uterine 
tone (TU) and hemodynamic changes.
Materials and Methods
This study was approved by the Hospital Ethics Committee. 
The subjects of this study were 60 singleton gestation pregnant 
women who were 38 weeks or more into their pregnancy, and 
were classified as Class 1 or 2 according to the American Society 
of Anesthesiologist (ASA) physical status classification and were 
supposed to undergo planned cesarean section under spinal 
anesthesia in the obstetrics and gynecology department in our 
hospital. The subjects were visited before the operation and 
written consent was given by the subjects. Pregnant women 
who had contraindication for spinal anesthesia, those whose 
weight was 100 kg or higher, those who had fetal abnormalities, 
diabetes, gestational hypertension, cardiovascular disease, or 
cerebral hemorrhage, and those whose labor pain had already 
started were excluded from the study. The age, height, and 
weight of the patients were recorded.
About 500 ml of Hartmann solution was rapidly dripped 
into all the parturient women before inducing anesthesia. An 
electrocardiograph, automated noninvasive blood pressure 
device, and a pulse oximeter were attached to the subjects, and 
oxygen was injected at 5 L/min through a mask. For the spinal 
anesthesia, the L3-4 or L4-5 lumbar region was punctured 
with a 25 G Quincke needle when the parturient women were 
in the left lateral recumbent position, and 0.5% hyperbaric 
bupivacaine solution (10-12 mg) was injected after verifying the 
cerebrospinal fluid leakage. Immediately after the anesthesia, 
the parturient women were asked to take the supine position 
and the maximum sensory block level was set to T4-6. The 
blood pressure and HR were measured in five-minute intervals 
from the time just after the anesthesia started to the end of the 
operation. However, during the 10 minutes after the oxytocin 
was injected, the blood pressure and HR were measured in 
one minute intervals, and delivery of the newborn was set as 
the baseline. The parturient women were asked if they felt or 
experienced nausea and vomiting after oxytocin injection and 
the results were recorded. When some of the parturient women 
had severe vomiting or continual nausea, the antiemetic drug, 
ondansetron 8 mg, was intravenously injected. In the cases where 
the systolic pressure decreased by more than 20% compared 
to the blood pressure before coming to the operating room, 
10 mg of ephedrine was intravenously injected until the blood 
pressure was normalized, and these cases were excluded from 
the study.
The subjects were randomly divided into three groups, 20 
subjects per group. For the oxytocin injection, 5 ml of bolus 
diluted with normal saline and 40 ml of infusion solution were 
prepared in advance by a nurse who did not participate in 
the study. In Group 1, bolus intravenous injection was done 
for about five seconds with 5 ml of normal saline and then 
continuous intravenous injection of 20 IU oxytocin diluted 
with 40 ml of normal saline was done at a rate of 0.5 IU/min 
for 40 minutes with a syringe pump. In groups 2 and 3, bolus 
intravenous injection of 2 IU and 5 IU of oxytocin diluted with 
5 ml of normal saline was done at a rate of 1 ml/sec, and then 
continuous intravenous injection of 10 IU of oxytocin diluted 
with 40 ml of normal saline was done at a rate of 0.25 IU/
min for 40 minutes with a syringe pump. The epidemiological 
data did not show a difference in the age, height, weight, and 
gestation period of the patients among the groups (Table 1). The 
obstetrician evaluated the degree of uterine contraction on a 
LAS in which the grade was determined from a grade of o to 10 484 www.ekja.org
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(0 = completely atonic, 10 = fully contracted) [15] at five-minute 
intervals during the operation for 25 minutes from the time just 
after the newborn was delivered. In the cases where the uterine 
contraction was considered as insufficient during the operation, 
intravenously injection of 0.2 mg of methylergonovine was 
done by the request of the obstetrician, diluting it with normal 
saline and slowly injecting it over one to two minutes with 
careful monitoring of the blood pressure. The blood loss was 
estimated by measuring the weight of the suction bottle and 
gauze excluding the amniotic fluid.
All the measured values obtained in the experiment were 
presented as the mean ± standard deviation and ‘n.’ ANOVA 
was done to compare age, weight, height, gestational age, 
fluid injection, and blood loss among the groups. An ANOVA 
was also performed to compare the HR and MAP among the 
group. To compare the degree of uterine contraction among 
the groups, Kruskal-Wallis test, a nonparametric method, was 
done. A repeated measures ANOVA was done to compare the 
HR, MAP, and degree of uterine contraction within a group. 
The Bonferroni method was used for the post-hoc test of the 
HR and MAP, and the Bonferroni correction was done for the 
post-hoc test of the degree of uterine contraction. A chi-square 
correlation analysis was done for each group to compare the 
frequency of vomiting and nausea and the number of times an 
antiemetic drug was used. All the statistical analyses were done 
with SPSS 15.0 (SPSS Inc., Chicago, IL, USA), with a significance 
level of 0.05.
Results
There was no significant difference in the age, weight, height, 
and gestational age among the groups (P > 0.05). Hemorrhage 
was 457.1 ± 15.5 ml in Group 1, 450.5 ± 13.9 ml in Group 2, and 
446.2 ± 13.6 ml in Group 3, with no significant difference (P > 
0.05, Table 1). The quantity of fluid injected during the operation 
was almost the same in all the groups, with no significant 
difference. The number of parturient women who experienced 
nausea and vomiting after intravenous injection of oxytocin 
and had antiemetic drugs administered was greater in groups 
1 and 2 than in Group 3, but there was no significant difference 
among the groups (P > 0.05). On the other hand, additional 
intravenous injection of uterotonic drug was required more 
in groups 2 and 3 than in Group1, but there was no significant 
difference among the groups (P > 0.05, Table 2).
The MAP was similar before the oxytocin intravenous injec-
tion. A maximum decrease of 4.5% was observed in Group 1 two 
minutes after intravenous injection of oxytocin whereas it was 
7.6% and 11.8% in groups 2 and 3, respectively, one minute after 
injection. However, the comparison within the groups showed 
that the maximum decrease was significant only in Group 3 (P < 
0.05, Table 3). There was no case where a hypertensor was used 
because of hypotension. The MAP decreased after intravenous 
injection of oxytocin and recovered after four minutes in each 
group. The comparison among the groups showed that the 
decrease in groups 2 and 3 at one minute after the injection was 
significantly greater than that in Group 1, and the decrease in 
Group 3 was significantly greater than that in Group 2 (P < 0.05, 
Fig. 1). 
The HR in each group was similar before the intravenous in-
jection of oxytocin. A maximum increase of 7.6% was observed 
Table 1. Maternal Demographic and Anesthetic Data
Group 1 Group 2 Group 3
Age (yr)
Weight (kg)
Height (cm)
Gestational age (weeks)
30.5 ± 3.5
67.5 ± 6.2
159.2 ± 4.0
39.0 ± 0.7
31.1 ± 3.1
69.2 ± 6.7
159.5 ± 3.8
38.7 ± 0.7
31.0 ± 2.8
68.8 ± 5.9
159.7 ± 4.2
38.6 ± 1.0
N = 20 in each group. Values are mean ± SD. Oxytocin was injected 
in the following doses; Group 1: 0.5 IU/min continuous injection, 
Group 2: 2 IU bolus-continuous injection, Group 3: 5 IU bolus-
con  tinuous injection. There was no significant difference among 
threegroups. 
Table 2. Anesthetic Maternal Demographic Data 
Group 1 Group 2 Group 3
Intravenous fluid (ml)
EBL (ml)
Additional uterotonic
  treatment (n)
Nausea (n)
Vomiting (n)
Antiemetic treatment (n)
1,897.3 ± 107.9
457.1 ± 15.5
6
2
1
1
1,962.0 ± 133.8 
450.5 ± 13.9
2
3
1
1
1,886.8 ± 83.0
446.2 ± 13.6
1
5
3
3
N = 20 in each group. Values are mean ± SD and No. of patients for 
the others. Oxytocin was injected in the following doses; Group 1: 
0.5 IU/min continuous injection, Group 2: 2 IU bolus-continuous 
injection, Group 3: 5 IU bolus-continuous injection. There was no 
significant difference among three groups. 
Table 3. Hemodynamic Change Data
Group 1 Group 2 Group 3
MAP (mmHg)
    Before oxytocin
    At max. change
HR (beats/min)
    Before oxytocin
    At max. change
93
89
93
98
93
86
92
107
94
 83*
93
 118*
N = 20 in each group. Values are maternal mean arterial pressure (MAP) 
and heart rate (HR). Measurements were performed before oxytocin 
and at the time of maximun changes. Oxytocin was injected in the 
following doses; Group 1: 0.5 IU/min continuous injection, Group 
2: 2 IU bolus-continuousinjection, Group 3: 5 IU bolus-continuous 
injection. *P < 0.05 compared to before oxytocin injection.485 www.ekja.org
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in Group 1 two minutes after intravenous injection of oxytocin 
while it was 17.0% and 26.1% in groups 2 and 3, respectively, 
one minute after the injection, but the increase was significant 
only in Group 3 (P < 0.05, Table 3). The comparison among 
the groups showed that the increase at one, two and three 
minutes after the injection was significantly greater in groups 
2 and 3 than that in Group 1, and the increase in Group 3 was 
significantly greater than that in Group 2. The increased HR 
recovered after five minutes in each group.
The degree of uterine contraction at five and ten minutes 
after the injection of oxytocin was significantly higher in 
groups 2 and 3 than that in Group 1 according to the LAS score 
based on the palpation of the obstetrician (P < 0.05). Parti-
cularly in Group 1, the LAS score at five minutes after the 
injection of oxytocin was 8.0, indicating the failure to obtain an 
appropriate degree of uterine contraction, and thus, another 
30% of additional uterotonic drug by intravenous injection 
was required. All the groups maintained an appropriate state 
of uterine contraction at ten minutes after the injection, and 
thereafter, no uterotonic drug by intravenous injection was 
additionally done because of re-relaxation.
Discussion
Oxytocin, a hormone that is secreted from the pituitary 
posterior lobe, decreases blood pressure by causing peripheral 
vasodilation and increasing the HR and induces uterine 
contraction [3,4]. Uterine contraction by oxytocin is enhanced 
since there are more intrauterine oxytocin receptors [16]. The 
oxytocin sensitivity of pregnant women reaches the maximum 
in the full term of the pregnancy because of the increase of 
intrauterine oxytocin receptors by gestational estrogen [10]. 
Hence, during normal delivery, the oxytocin discharged from 
the pituitary posterior lobe by the obstetric canal stimulus of the 
fetus can induce labor pain and sufficient uterine contraction 
with an extreme low-dose of 10 mIU/min [17]. In the case of a 
planned cesarean section, however, a relatively high-dose of 
oxytocin (5-20 IU) is intravenously injected since the action 
of the oxytocin is not normal [11,12]. Since hemodynamic 
changes are proportional to the intravenously injected dose of 
oxytocin, studies have been done on effective concentrations 
and intravenous injection methods.
Sarna et al. [11] reported that oxytocin infusion at a rate of 
1 IU/min did not show any difference in uterine contraction 
and blood loss with that of 5 IU by intravenous injection even 
though the total dose may have been more than 5 IU. Kim et 
al. [12] published the same assertion. On the contrary, Zarzur 
[18] recommended an infusion at a rate lower than 1 IU/min 
because infusion at a rate higher than 0.25 IU/min may cause 
such symptoms as hemangiectatic hypotension, tachycardia, 
increased cardiac output, and myocardial ischemia. In Group 
1, in this study, where the infusion was done at the rate of 0.5 
IU/min, there was no significant hemodynamic change due to 
the infusion of oxytocin, but about another 30% of additional 
uterotonic drug was required for parturient women to obtain an 
appropriate degree of uterine contraction.
According to many recent studies, oxytocin bolus injection 
was reported to be more effective than infusion by intravenous 
injection to reduce blood loss by inducing the appropriate 
uterine contraction [13], and thus, the minimum bolus dose 
has been discussed [19-21]. A suggested method to reduce 
hemodynamic changes is the repeated intravenous injections of 
a small quantity of a bolus dose and bolus-continuous parallel 
intravenous injection [14,22]. Svanström et al. [6] stated that 
attention is required because a bolus injection of 10 IU oxytocin 
may cause temporary hypotension and tachycardia as well as 
myocardial ischemia, apart from the operation, pregnancy, 
and autonomic blocking by spinal anesthesia. Pinder et al. 
[2] recommended 5 IU as the bolus dose since 10 IU of bolus 
intravenous injection caused severe hemodynamic changes, 
but they stated that the dose might not be considered as safe, 
either. On the contrary, Butwick et al. [20] asserted that a dose 
of more than 5 IU might not be necessary because appropriate 
uterine contraction occurred even with a bolus dose of 0.5-
3 IU. Sartain et al. [14] injected 2 IU and 5 IU of bolus doses, 
which are the same doses for groups 2 and 3 in our experiment 
and reported that the use of 2 IU was more effective because the 
hemodynamic changes were more severe in the 5 IU group even 
though the uterine contraction were similar in the two groups. 
These results were similar to our results and the hemodynamic 
changes were always temporary.
Fig. 1. Change of maternal mean arterial pressure (MAP) after 
oxytocin injection during Cesarean delivery. Oxytocin was injected 
in the following doses; Group 1: 0.5 IU/min continuous injection, 
Group 2: 2 IU bolus-continuous injection, Group 3: 5 IU bolus-
continuous injection. *P < 0.05 compared with each group after 
oxytocin injection.486 www.ekja.org
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In the case of Group 3 in which 5 IU bolus-continuous intra-
venous injection was done, the MAP and HR were significantly 
decreased by 11.8% and significantly increased by 26.1%, 
respectively, at one minute after the injection of oxytocin. On 
the contrary, the MAP and HR were not significantly changed in 
Group 2 in which 2 IU bolus-continuous intravenous injection 
was done (Fig. 1, 2, Table 3). Thus, it was found that the 
hemodynamic changes varied by the bolus injected oxytocin 
dose and changes were recovered from in about 4-5 minutes 
after oxytocin injection. As shown in this study, delivery of 
the newborn and the following excitement may affect the HR 
because parturient women are conscious during cesarean 
section under spinal anesthesia. However, the main factor of 
the changes may be the effect of oxytocin itself.
The half-life of oxytocin is about 5-12 minutes and a blood 
steady state is reached in about 30-60 minutes after intravenous 
injection [23,24]. Thus, the oxytocin dose and injection method 
play an important role in the hemodynamic changes before 
a steady state is reached. These hemodynamic changes by 
oxytocin are always temporary and the effect on healthy 
parturient women is small. However, they may be dangerous 
to parturient women who have hypovolemia or cardiovascular 
diseases. Hence, continuous intravenous injection of oxytocin 
at a low concentration is primarily recommended as a safe 
injection method for parturient women in a high-risk group 
[1,2]. Nevertheless, repeated bolus intravenous injection with 
a small quantity of bolus or parallel intravenous injection of a 
small quantity of bolus plus continuous injection is also used 
because of the rapid desensitization by which the hemodynamic 
changes are significantly decreased in the repeated oxytocin 
than in the initial injection [14,22]. In our study, a longer time 
was taken in the continuous intravenous injection group (Group 
1) to induce the appropriate uterine contraction with a LAS 
score of 8.0 than the bolus-continuous parallel intravenous 
injection groups (groups 2 and 3), and about another 30% of 
additional uterotonic drug was required in Group 1, but there 
was no significant difference in the mean blood loss. Nausea 
and vomiting occurred more in Group 3, but the difference was 
not significant (Table 2, Fig. 3).
In conclusion, with parturient women undergoing planned 
cesarean section under spinal anesthesia, infusion of 20 IU of 
oxytocin was done at a rate of 0.5 IU/min, and 2 IU or 5 IU bolus 
intravenous injection followed by 10 IU oxytocin intravenous 
injection at a rate of 0.25 IU/min were done immediately 
after clamping of the umbilical cord following delivery of the 
new born, and the results show that a more effective uterine 
contraction occurred in the bolus-continuous parallel intra-
venous injection group accompanied by a decreased MAP and 
increased mean HR which were significantly higher in the 2 IU 
bolus-continuous parallel intravenous injection group than in 
the 5 IU bolus-continuous parallel intravenous injection group. 
These changes may have little effect on healthy parturient 
women because they can recover within about 4-5 minutes 
after intravenous injection of oxytocin, as in this study, but the 
methods that cause the changes are difficult to interpret in 
women who have uterine atony such as premature separation 
of placenta or placenta accrete. Although a low-dose bolus 
intravenous injection may be appropriate to meet the demand 
Fig. 2. Change of heart rate (HR) after oxytocin injection during 
Cesarean delivery. Oxytocin was injected in the following doses; 
Group 1: 0.5 IU/min continuous injection, Group 2: 2 IU bolus-
continuous injection, Group 3: 5 IU bolus-continuous injection. *P < 
0.05 compared with each group after oxytocin injection.
Fig. 3. Prevalence of adequate uterine tone (UT) by linear analog 
scale (LAS) after oxytocin injection during Cesarean delivery. Oxyto-
cin was injected in the following doses; Group 1: 0.5 IU/min conti-
nuous injection, Group 2: 2 IU bolus-continuous injection, Group 
3: 5 IU bolus-continuous injection. Numerical scores for UT were 
assessed by the obstetrician using a linear analog scale of 0 (absent 
UT) to 10 (optimal UT). *P < 0.05 compared with each group after 
oxytocin injection.487 www.ekja.org
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of obstetricians who want rapid uterine contraction, they should 
be careful when using this method in parturient women who 
are suspected to have hypovolemia or cardiovascular diseases 
because bolus-continuous parallel intravenous injection of 2 IU 
oxytocin is accompanied by hemodynamic changes in MAP and 
HR though they may be relatively mild. Further studies need to 
be conducted on low-dose intravenous injection with less than 
2 IU oxytocin in order to obtain more stable and objective data.
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